SLC5A2 and diabetes mellitus: In the sub-analysis by duration of diabetes diagnosis, both groups (<10 years and ≥10 years) showed a significant decrease in all-cause mortality associated with SGLT2 inhibitor use compared with placebo and DPP4 inhibitor use.